NEW SULFA GLYCYR IRIS

Ophthalmic Medicines

♦ NEW SULFA GLYCYR IRIS is an eye drop that contains sustainable antibacterial agent sodium sulfamethoxazole that has an excellent antibacterial effect over bacteria that cause sty and conjunctivitis, and ingredients that relieve inflammation and itching in the eye.

Indication

Conjunctivitis (pink-eye), chalazia, blepharitis (running eye), itchy eyes

Dosage and administration

Instill 2 to 3 drops per dose 3 to 6 times daily.

Comply with the prescribed dosage and administration instructions.

When allowing children to use the medicine, a guardian must be present to watch and tell such them how to use it. Do not touch the tip of the container with the eyelid or eyelash. Do not use the drug when the solution becomes turbid.

Do not use the drug when you are wearing soft contact lenses.

Use this only as an eye drop.

ingredient and amount

Sodium Sulfamethoxazole 4.00%

Dipotassium Glycyrrhizinate 0.25%

Chlorpheniramine Maleate 0.03%

Taurine (Aminoethyl Sulfonic Acid) 0.10%

Excipients

Sodium borate,pH adjusting agent,Benzalkonium chloride,Edetate sodium,Polysorbate 80

Precautions relating to ingredient and amount

No need to worry if you taste bitterness or sweetness in the mouth when administering the drug. The bitterness is caused by sulfamethoxazole, which is an active ingredient, and the sweetness is caused by dipotassium glycyrrhizinate, which is an active ingredient.

Precautions

When not to use the product

(If you do not follow these instructions, the current symptoms may worsen or adverse reactions are more likely to occur.)

• Do not take this medicine for a long time

Consultation

• The following persons should contact a physician, pharmacist, or registered salesperson for a consultation before use. Patients undergoing medical treatment from a physician

Patients who have experienced allergic symptoms associated with drugs, etc.

Persons with the following symptoms:

Severe eye pain

If the following symptoms are observed after taking this drug, these may be adverse reactions, so immediately discontinue the use of this drug, and show this document to your physician, pharmacist, or registered salesperson for a consultation. Skin

rash/redness

itching

Eyes:

congestion of the eye

itching

swelling

• If symptoms do not improve even after using this medicine for 3 to 4 days, stop taking this medicine and consult a physician, pharmacist or registered salesperson, being sure to take this instruction leaflet with you.

Precautions for storage and handling

Store in a cool, low humidity place away from direct sunlight.

Store the product beyond the reach of children.

Do not transfer the drug to other containers. (It may lead to misuse or quality deterioration)

Do not share the drug with other people.

Do not leave the drug under high temperatures, such as on a car dashboard. (It may result in the deformation of the container and the degradation of the drug solution.)

Do not use the product past the expiration date. Even within the expiration date, try to use it up as soon as possible once it is opened (to assure the quality).

The crystalized ingredient may accumulate at the tip of the container and inside the cap depending on the storage

11-Jul-2019 1/2 page

82

[Disclaimer on Multilingual OTC Product Information]

- •This product is a pharmaceutical product approved under a Japanese law, the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices, with a view to its sale and use in Japan.
- •Multilingual product information is a translation of the product labeling written in Japanese and provided for your information only. It does not warrant that its contents and the product itself conforms to laws and regulations in countries other than Japan.
- •Multilingual product information is a tentative translation by the provider (or Our Company), and may be modified or altered without notice.
- •The provider (or Our Company) assumes no responsibility for any occurred problem attributable to the contents of the multilingual product information.

11-Jul-2019 2/2 page